Press releaseGlobe Newswire
Pliant Therapeutics
PLRX · NASDAQ
$0.9124+$0.0137 (+1.52%)TodayMarket closed ·
Prev close $0.8987
Latest news
- Press releaseGlobe Newswire
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
- Press releaseGlobe Newswire
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
- Press releasePRNewswire
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
- Press releaseGlobe Newswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
- Press releaseGlobe Newswire
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
- Press releaseGlobe Newswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
- Press releaseGlobe Newswire
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
- Press releaseGlobe Newswire
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
- Press releaseGlobe Newswire
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
Pliant Therapeutics Provides Update on BEACON-IPF
- Press releaseGlobe Newswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
- Press releaseGlobe Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
- Press releasePRNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
- Press releaseGlobe Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX
- Press releaseGlobe Newswire
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
- Press releasePRNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
- Press releaseGlobe Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX
- NewsVandana Singh
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future
- Press releaseGlobe Newswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
- NewsAvi Kapoor
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
- NewsAvi Kapoor
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- NewsAvi Kapoor
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.